Skip to content

In the BioHarmony Drug Report Database

Abametapir

Xeglyze (abametapir) is a small molecule pharmaceutical. Abametapir was first approved as Xeglyze on 2020-07-24. It is used to treat pediculus in the USA. Xeglyze's patents are valid until 2034-12-17 (FDA).
Trade Name Xeglyze
Common Name Abametapir
Indication pediculus
Drug Class Pediculicide, metalloproteinase inhibitor
Abametapir
Get full access now